Safety of Peritoneal Dialysis after Nonrenal Solid-Organ Transplantation

2018 ◽  
Vol 38 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Anne Buffet ◽  
Sonia Guillouët ◽  
Thierry Lobbedez ◽  
Maxence Ficheux ◽  
Antoine Lanot ◽  
...  

Background End-stage renal disease is a well-known complication after solid-organ transplantation, mostly as a result of calcineurin-inhibitor therapy. Among recipients of solid-organ transplants other than kidneys, peritoneal dialysis (PD) has been considered an accessory technique as an increased risk of infectious complications has been reported. The aim of our study was to evaluate the outcome of patients with a liver, heart, or lung transplant who underwent PD for replacement therapy. Methods This was a retrospective, monocentric study. Every adult patient starting PD between January 1, 2001, and December 31, 2016, at our center was included. The history of previous solid-organ transplantation was determined. For the statistical analysis, we considered 2 groups of patients: 1 group having a history of transplantation of an organ other than the kidney (lung, heart, liver), and 1 group that was starting dialysis without any prior history of organ transplantation. Patients who had previously undergone kidney transplantation were excluded. The events of interest were the first peritonitis episode, death, and PD failure, defined as transfer to hemodialysis. Results A total of 383 patients started PD during this period, 13 of whom had a history of organ transplantation. We found no significant difference between the solid-organ transplantation patients and those without a history of transplantation in terms of the occurrence of peritonitis (HR [hazard ratio] 0.91 [0.37 – 2.22]), death (HR 0.83 [0.26 – 2.63]), and PD failure (HR 1.01 [0.32 – 3.22]). Conclusion Peritoneal dialysis appears to be an effective replacement therapy for patients with a previous history of solid-organ transplantation.

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e043731
Author(s):  
Adnan Sharif ◽  
Javeria Peracha ◽  
David Winter ◽  
Raoul Reulen ◽  
Mike Hawkins

IntroductionSolid organ transplant patients are counselled regarding increased risk of cancer (principally due to their need for lifelong immunosuppression) and it ranks as one of their biggest self-reported worries. Post-transplantation cancer is common, associated with increased healthcare costs and emerging as a leading cause of post-transplant mortality. However, epidemiology of cancer post-transplantation remains poorly understood, with limitations including translating data from different countries and national data being siloed across different registries and/or data warehouses.Methods and analysisStudy methodology for Epidemiology of Cancer after Solid Organ Transplantation involves record linkage between the UK Transplant Registry (from NHS Blood and Transplant), Hospital Episode Statistics (for secondary care episodes from NHS Digital), National Cancer Registry (from cancer registration data hosted by Public Health England) and the National Death Registry (from NHS Digital). Deterministic record linkage will be conducted by NHS Digital, with a fully anonymised linked dataset available for analysis by the research team. The study cohort will consist of up to 85 410 solid organ transplant recipients,who underwent a solid organ transplant in England between 1 January 1985 and 31 December 2015, with up-to-date outcome data.Ethics and disseminationThis study has been approved by the Confidentiality Advisory Group (reference: 16/CAG/0121), Research Ethics Committee (reference: 15/YH/0320) and Institutional Review Board (reference: RRK5471). The results of this study will be presented at national and international conferences, and manuscripts with results will be submitted for publication in high-impact peer-reviewed journals. The information produced will also be used to develop national evidence-based clinical guidelines to inform risk stratification to enable risk-based clinical follow-up.Trial registration numberNCT02991105.


2019 ◽  
Vol 130 (3) ◽  
Author(s):  
Zaid Al‐Qurayshi ◽  
Jarrett Walsh ◽  
Scott Owen ◽  
Gregory Randolph ◽  
Emad Kandil

2013 ◽  
Vol 95 (10) ◽  
pp. 1183-1186 ◽  
Author(s):  
Colleen M. Krajewski ◽  
Duvuru Geetha ◽  
Veronica Gomez-Lobo

Spine ◽  
2014 ◽  
Vol 39 (19) ◽  
pp. E1154-E1158 ◽  
Author(s):  
Jonathan Falakassa ◽  
Brandon P. Hirsch ◽  
Robert P. Norton ◽  
Matthew Mendez-Zfass ◽  
Frank J. Eismont

Author(s):  
Marie Wright ◽  
Mark Chilvers ◽  
Tom Blydt-Hansen

Background Solid organ transplantation (SOT) has become commonly used in children and is associated with excellent survival rates into adulthood. Data regarding long-term respiratory outcomes following pediatric transplantation are lacking. We aimed to describe the prevalence and nature of respiratory pathology following pediatric heart, kidney, and liver transplant, and identify potential risk factors for respiratory complications. Methods Retrospective review involving all children under active follow-up at the provincial transplant service in British Columbia, Canada, following SOT. Results Of 118 children, 33% experienced respiratory complications, increasing to 54% in heart transplant recipients. Chronic or recurrent cough with persistent chest x-ray changes was the most common clinical picture, and most infections were with non-opportunistic organisms typically found in otherwise healthy children. A history of respiratory illness prior to transplant was significantly associated with risk of post-transplant respiratory complications. 8% were diagnosed with bronchiectasis, which was more common in recipients of heart and kidney transplant. Bronchiectasis was associated with recurrent hospital admissions with lower respiratory tract infections, treatment of acute rejection episodes, and treatment with sirolimus. Interpretation Respiratory morbidity is common after pediatric SOT, and bronchiectasis rates were disproportionately high in this patient group. We hypothesise that this relates to recurrent infections resulting from iatrogenic immunosuppression. Direct pulmonary toxicity from immunosuppression drugs may also be contributory. A high index of suspicion for respiratory complications is needed following childhood SOT, particularly in those with a history of respiratory disease prior to transplant, experiencing recurrent or severe respiratory tract infections, or exposed to intensified immunosuppression.


Sign in / Sign up

Export Citation Format

Share Document